

## Accepted Manuscript

DKK1 and sclerostin are early markers of relapse in multiple myeloma

Charlotte Mabile, Adeline Ruysen Witrand, Yannick Degboe, Isabelle Gennero, Herve Avet Loiseau, Murielle Roussel, Benjamin Hebraud, Delphine Nigon, Michel Attal, Michel Laroche



PII: S8756-3282(17)30370-8  
DOI: doi:[10.1016/j.bone.2017.10.004](https://doi.org/10.1016/j.bone.2017.10.004)  
Reference: BON 11444  
To appear in: *Bone*  
Received date: 26 June 2017  
Revised date: 21 September 2017  
Accepted date: 4 October 2017

Please cite this article as: Charlotte Mabile, Adeline Ruysen Witrand, Yannick Degboe, Isabelle Gennero, Herve Avet Loiseau, Murielle Roussel, Benjamin Hebraud, Delphine Nigon, Michel Attal, Michel Laroche , DKK1 and sclerostin are early markers of relapse in multiple myeloma. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Bon(2017), doi:[10.1016/j.bone.2017.10.004](https://doi.org/10.1016/j.bone.2017.10.004)

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

# DKK1 and sclerostin are early markers of relapse in multiple myeloma

Charlotte MABILLE<sup>1</sup>, Adeline RUYSEN WITRAND<sup>1</sup>, Yannick DEGBOE<sup>1,2</sup>, Isabelle GENNERO<sup>3</sup>, Herve AVET LOISEAU<sup>4</sup>, Murielle ROUSSEL<sup>5</sup>, Benjamin HEBRAUD<sup>5</sup>, Delphine NIGON<sup>1</sup>, Michel ATTAL<sup>5</sup>, Michel LAROCHE<sup>1</sup>

<sup>1</sup> Centre de rhumatologie, hopital Purpan, 1 place du docteur Joseph Baylac 31300 Toulouse, France

<sup>2</sup> INSERM U1043 - CNRS UMR 5282, CPTP, Université Paul Sabatier, Toulouse, France

<sup>3</sup> Biochimic Center, Purpan University Hospital, Toulouse, France

<sup>4</sup> Unite de Genomique du Myelome, IUC-T Oncopole, 1 Avenue Irene Joliot-Curie, 31059, Toulouse, France

<sup>5</sup> Institut Universitaire du Cancer de Toulouse-Oncopole, 1 Avenue Irene Joliot-Curie, 31059, Toulouse, France

## Authorship Contributions:

CM and ARW contributed equally to the conception of the study, interpretation of the data and manuscript preparation

YD was involved in the study conception and manuscript preparation

IG was responsible for the DKK1, sclerostin and P1NP dosages and the manuscript preparation

HAL, MR, BH, MA were involved in the conception of IFM2009 protocol, study coordination, patient's inclusion and follow-up and participate to the manuscript preparation

DN was responsible for statistical analyses and manuscript preparation

ML was involved in the study conception, analyses interpretation and manuscript preparation.

Running Heads: DKK1 and sclerostin in multiple myeloma

Corresponding author:

Dr Charlotte MABILLE

Centre de Rhumatologie, Hôpital Pierre Paul Riquet, CHU Toulouse

Tel.: +33 (0)5 61 77 69 76

mabille.c@chu-toulouse.fr

Download English Version:

<https://daneshyari.com/en/article/8624852>

Download Persian Version:

<https://daneshyari.com/article/8624852>

[Daneshyari.com](https://daneshyari.com)